United States

Analyst Research Report Snapshot


ChronTech Pharma AB (CTEC) - Financial Analysis Review






10 Feb 2014





Companies referenced:


Available for Immediate Download

ChronTech Pharma AB (CTEC) - Financial Analysis Review Summary ChronTech Pharma AB (ChronTech Pharma) is a pharmaceutical company. It develops and commercializes drugs against chronic disease that are based on proprietary and patented technologies. The products offered by the company are ChronVac-C, ChronVac-B, ChronSeal and RAS. It focuses on research and development projects. It acts against chronic hepatitis C virus and hepatitis B virus infections. ChronVac-C is also a genetic vaccine. ChronVac-C and ChronVac-B is a therapeutic vaccine. GlobalData's ChronTech Pharma AB (CTEC) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. ChronTech Pharma AB Key Recent Developments: Sep 24, 2013: ChronTech's IVIN technology allows for lower vaccine doses with maintained efficacy Aug 23, 2013: ChronTech Pharma Reports H1 2013 Results May 03, 2013: ChronTech Pharma Reports Q1 2013 Results Mar 28, 2013: Changes to the chrontech pharma board of directors Jan 25, 2013: ChronTech Pharma Reports 2012 Results This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.